

AMENDMENTS TO THE CLAIMS

Claims 1-20 (cancelled).

Claim 21 (previously presented). An isolated oligopeptide consisting of 12 amino acid residues and having a hydropathy profile in which the side chains of the amino acid residues 2, 5 and 9 have positive hydropathy values, the side chains of amino acid residues 3, 4, 8 and 11 have negative hydropathy values, and the side chains of amino acid residues at positions 1, 6, 7, 10 and 12 can have either positive or negative hydropathy values; the oligopeptide being capable of mediating cell permeability to substances that are to be transported into a cell when the oligopeptide is linked to the substance by a covalent or non-covalent linkage.

Claim 22 (previously presented). A fusion protein comprising a polypeptide covalently linked to an oligopeptide of claim 21.

Claim 23 (previously presented). The fusion protein of claim 22 wherein the polypeptide is selected from the group consisting of a structural polypeptide, a tumor necrosis factor, an interferon, an interleukin, a lymphokine, a growth factor, and a plasma protein.

Claim 24 (previously presented). The fusion protein of claim 22 wherein the polypeptide is a cytokine.

Claim 25 (previously presented). The fusion protein of claim 22 wherein the polypeptide is a co-stimulatory molecule.

Claim 26 (previously presented). The fusion protein of claim 22 wherein the polypeptide is a tumor-associated antigen.

Claim 27 (previously presented). The fusion protein of claim 22 wherein the polypeptide is a peptide fragment of a viral coat.

Claim 28 (previously presented). The fusion protein of claim 22 wherein the polypeptide is a hormone.

Claim 29 (previously presented). The fusion protein of claim 22 wherein the polypeptide is a ribozyme.

Claim 30 (previously presented). An isolated oligopeptide consisting of 12 amino acid residues and having an amino acid residue sequence selected from the group consisting of SEQ

ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, and SEQ ID NO: 13.

Claim 31 (previously presented). A fusion protein comprising a polypeptide covalently linked to an oligopeptide of claim 30.

Claim 32 (previously presented). The fusion protein of claim 31 wherein the polypeptide is selected from the group consisting of a structural polypeptide, a tumor necrosis factor, an interferon, an interleukin, a lymphokine, a growth factor, and a plasma protein.

Claim 33 (previously presented). The fusion protein of claim 31 wherein the polypeptide is a cytokine.

Claim 34 (previously presented). The fusion protein of claim 31 wherein the polypeptide is a co-stimulatory molecule.

Claim 35 (previously presented). The fusion protein of claim 31 wherein the polypeptide is a tumor-associated antigen.

Claim 36 (previously presented). The fusion protein of claim 31 wherein the polypeptide is a peptide fragment of a viral coat.

Claim 37 (previously presented). The fusion protein of claim 31 wherein the polypeptide is a hormone.

Claim 38 (previously presented). The fusion protein of claim 31 wherein the polypeptide is a ribozyme.